Published in New England Journal of Medicine · View the paper (DOI)
The study found that remdesivir reduced the median time to recovery by 4 days compared to placebo, with a survival benefit and improved clinical status. The findings support remdesivir as the standard treatment for hospitalized COVID-19 patients requiring supplemental oxygen therapy.
Coverage from 2 institutions